Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

POONGJEON PHARMACY CO.,LTD.

풍전약품298060KOSDAQSector: Pharma & Biotech
₩2,4552.39%Market cap ₩23.7BAs of Sep 2, 2026 close · updated once daily
Market cap
₩23.7B
#1543 in KOSDAQ
119.7x
Sector median 16.3x (profitable cos.)
0.67x
Sector median 1.61x
0.0%
Sector median 0.0%
D
Grade D60.5 ptsTop 32% of 2,523 graded stocksPreviously BMethodology v2.0
Financial strength
54.0/100
Price attractiveness
71.3/100
Shareholder Return
37.5/100

As of Sep 2, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCDCurrentF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band D with a total score of 60.5 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

ⓘ Grade capped based on disclosed facts: designated as administrative issue

ⓘ Growth momentum not rated — will be included automatically as data accumulates

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩2,450High ₩6,275
Latest close
Price change by period
1W
0.20%
1M
5.50%
3M
10.50%
1Y
49.40%

Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.

As of the Sep 2, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

54.0/100
How much debt does it carry relative to equity?
44.1%
Sector median 51.6%
Sector lowhighTop 41.9% in sector
Can it cover what's due within a year?
227.7%
Sector median 191.7%
Sector lowhighTop 41.9% in sector
How much of revenue becomes profit?
-19.0%
Sector median -2.4%
Sector lowhighBottom 40.4% in sector
How much did it earn on its own capital?
0.6%
Sector median -4.5%
Sector lowhighTop 40.7% in sector

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

71.3/100
Is the price expensive relative to earnings?
119.7x
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighTop 37.4% in sector
Is the price expensive relative to book value?
0.67x
Sector median 1.61x
Sector lowhighTop 20% in sector

Valuation uses the Sep 2, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
6,638 shares (0.0% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 1 met · 3 not met · 5 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩203M
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩5.3B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
-₩5.3B vs ₩203M
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
20,467,248 → 44,203,176
Operating margin up
Whether operating income over revenue rose from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026B→D

Methodology version change (v2.0 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 4,734,848 new shares, equal to 12.0% of shares outstanding before the increase (filed 2025-10-17). 4 filings meeting the same criteria were disclosed in the past 24 months. View filing ↗

Private CB/BW issuance resolutions (past 36 months)

3 private-placement convertible bond (CB) / bond-with-warrants (BW) issuance resolutions were disclosed in the past 36 months (latest filing 2026-06-10). View filing ↗

CB with conversion-price adjustment clause (past 36 months)

3 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2026-06-10). View filing ↗

CEO (representative executive officer) change filings (past 36 months)

3 CEO (representative executive officer) change filings were submitted in the past 36 months (latest filing 2025-07-18). View filing ↗

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Convertible bond issuanceJun 10, 2026Source ↗
Paid-in capital increaseJun 10, 2026Source ↗
Periodic report filedMay 14, 2026Source ↗

View in the filings calendar →